Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewLY 235959
说明： Competitive NMDA antagonist
化学名： [3S-(3α,4aα,6β,8aα)]-Decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid)
生物活性 for LY 235959
LY 235959 is a competitive NMDA receptor antagonist.
许可信息
Sold with the permission of Eli Lilly and Company.
技术数据 for LY 235959
| 分子量 | 277.26 |
| 公式 | C11H20NO5P |
| 储存 | Desiccate at +4°C |
| CAS Number | 137433-06-8 |
| PubChem ID | 131938 |
| InChI Key | STIRHCNEGQQBOY-QEYWKRMJSA-N |
| Smiles | [H][C@]12[C@](CC[C@H](CP(O)(O)=O)C2)([H])CN[C@H]([C@](O)=O)C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for LY 235959
参考文献 for LY 235959
参考文献是支持产品生物活性的出版物。
Borowicz et al (1996) Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice. Epilepsia 37 618 PMID: 8681893
Ellison (1994) Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 5 2688 PMID: 7696633
按产品操作查看相关产品
关键词: LY 235959, LY 235959 supplier, Competitive, NMDA, antagonist, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, LY235959, 1019, Tocris Bioscience
2 篇 LY 235959 的引用文献
引用文献是使用了 Tocris 产品的出版物。 LY 235959 的部分引用包括：
Kenny et al (2009) NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology 34 266 PMID: 18418357
Fowler et al (2011) Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature 471 597 PMID: 21278726
LY 235959 的评论
目前没有该产品的评论。 Be the first to review LY 235959 and earn rewards!
Have you used LY 235959?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.